Diseases of the brain can be caused by both hereditary and environmental factors, both of which modulate neuronal development and function (van Loo & Martens, 2007). With recent advances in neuronal differentiation technology using iPS cells, it is possible to study the neurodevelopment and neuropathology of AUDs in humans ex vivo. Reprogramming is reliant on the efficient delivery and expression of (TFs) into a number of somatic cell types (Um, 2012). The main differences in reprogramming arise from the cell types, species and delivery method. Dermal fibroblasts are the most commonly used donor somatic cells for reprogramming (González, Boué, & Izpisúa Belmonte, 2011; Raab, Klingenstein, Liebau, & Linta, 2014). Fibroblasts contain many attractive characteristics that make them ideal for reprogramming, including the ease of cultivation in culture and low methylation levels of the promoter regions for genes expressed in the early embryo, such as OCT4 and NANOG, thus granting the appropriate TFs access to the promoter (Raab et al., 2014). Within ~ 5 weeks in culture, a small percentage (≤ 1%) of the initial somatic cells are reprogrammed to pluripotent
